[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 25, 2001

Raloxifene for Breast Cancer Prevention

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(16):2079. doi:10.1001/jama.285.16.2079

To the Editor: Mr Vastag's Medical News & Perspectives article1 failed to present a balanced view regarding recruitment challenges for the Study of Tamoxifen and Raloxifene (STAR) trial and contained inaccurate and misleading information about raloxifene hydrochloride and Eli Lilly and Company.

Vastag correctly states that enrollment for STAR is nearly on target. Nevertheless, he reports study sites have faced challenges in meeting enrollment goals because physicians "have already decided that raloxifene is a better choice [than tamoxifen]." This claim is unsubstantiated and oversimplifies the complex dynamics of enrolling postmenopausal women in breast cancer trials.

First Page Preview View Large
First page PDF preview
First page PDF preview
×